MYGN

Myriad Genetics, Inc. - 10-Q Summary (Quarter Ended Sept 30, 2001)

Business Context and Reporting Period

This is a quarterly report (Form 10-Q) for Myriad Genetics, Inc., a biopharmaceutical company focused on therapeutic and predictive medicine products. The reporting period covers the three months ended September 30, 2001. The company operates two primary segments: Research (gene discovery and therapeutic development) and Predictive Medicine (genetic testing for disease predisposition).

Key Financial Metrics

Liquidity: The company holds significant liquid assets, with cash and cash equivalents of $47.4 million and marketable investment securities totaling approximately $88.9 million ($49.2 million current + $39.7 million long-term). Total current liabilities are $22.0 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 22% year-over-year. Predictive medicine revenue surged 81% to $5.52 million, driven by the launch of COLARIS and increased sales efforts. Research revenue declined slightly to $7.67 million due to a strategic shift toward internal development and reduced collaboration expenses.
• Expense Trends: Research and development (R&D) expenses decreased 6% to $8.26 million, partially offset by reimbursements from a 50% owned affiliate (Myriad Proteomics). Selling, general, and administrative (SG&A) expenses increased 43% to $5.62 million, primarily due to the expansion of the sales force from 41 to 75 employees and the launch of the MELARIS product.
• Profitability: The net loss improved by approximately 44% compared to the prior year, narrowing from $2.07 million to $1.19 million. This improvement was aided by higher interest income ($1.93 million vs. $1.40 million) resulting from a larger cash position.
• Cash Flow: Net cash used in operating activities increased to $9.82 million (from $5.29 million), largely due to a decrease in deferred revenue and payments for prior quarter equipment. However, investing activities provided $20.8 million in cash due to the sale of marketable securities.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur losses for at least the next several years due to continued expansion of R&D, drug discovery, and predictive medicine marketing. The company believes it has adequate capital resources to fund operations for at least the next two years.
• Capital Raising: On November 9, 2001, the company filed a Form S-3 shelf registration statement to sell up to $250 million of various securities. This registration was not yet effective at the time of filing.
• Risks: Key risks include the inability to achieve commercial success for new products, delays in clinical trials, dependence on pharmaceutical collaborations, and the potential for patent infringement claims. The company also faces market risks related to interest rate fluctuations affecting its investment portfolio.
• Unusual Items: The company adopted a stockholder rights plan (poison pill) in July 2001. Additionally, R&D expenses were reduced by $1.97 million due to scientific outsourcing services provided to Myriad Proteomics, Inc.

Investor Verification Checklist

• Verify the status and effectiveness of the $250 million Form S-3 shelf registration filed in November 2001.
• Monitor the progress of the lead therapeutic product for prostate cancer, which recently completed Phase II trials.
• Assess the sustainability of the 81% growth in predictive medicine revenue following the launch of MELARIS and COLARIS.
• Review the terms of the stockholder rights plan adopted in July 2001 and its potential impact on future M&A activity.
• Track the burn rate of cash given the increased SG&A expenses and the expectation of continued losses.